Impact of delaying treatment intensification with a glucagon-like peptide-1 receptor agonist in patients with type 2 diabetes uncontrolled on basal insulin: A longitudinal study of a US administrative claims database.
Liyue TongChunshen PanHongwei WangMonica BertoliniElisheva LewLuigi F MeneghiniPublished in: Diabetes, obesity & metabolism (2017)
Timely addition of a GLP-1 RA to therapy for patients with T2D who were not adequately controlled with basal insulin is associated with better clinical and economic outcomes.